Stocks to Watch – Athersys Inc. (ATHX)

Stocks to Watch – Athersys Inc. (NASDAQ: ATHX)

Incorporated in 1995, Athersys, Inc. Incorporated is a biopharmaceutical company which is engaged in the discovery and development of therapeutic product candidates. The Company has established a pipeline of therapeutic product development programs in multiple disease areas. The company’s product development portfolio includes MultiStem, a stem cell product that it had developed as a treatment for multiple disease indications, and is being evaluated in clinical trials. Treatment for obesity and related metabolic conditions are likewise developed by the Company by focusing on the development of compounds which would act through the stimulation of a specific receptor in the brain that controls appetite. It also focuses on the development of  small molecule compounds for the treatment of certain neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. In 2010, the Company together with RTI Biologics Inc. entered into an agreement for the development and commercialization of multiptent adult progenitor cell technology-based biologic implants which are used for orthopedic applications.

Through MultiStem, The Company has established therapeutic product development programs for the treatment of certain areas including:

• cardiovascular disease,
• neurological disease
• immune system disorders.

In the year 2010, several programs had been created by the company under the clinical development stage. These programs include the following

• Phase II clinical study which involves the administration of MultiStem to patients suffering from Ulcerative colitis, which study is authorized by the US Food and Drug Administation
• Phase I clinical study involving administration of MultiStem to patients suffering from an acute myocardial infarction (AMI), more commonly referred to as a heart attack
• Phase I clinical study involving administration of MultiStem to patients suffering from leukemia or certain other blood-borne cancers.

Athersys, Inc. (NASDAQ: ATHX) 52 week: 1.00 – 3.02   Mkt cap: 40.57M   Shares:  29.40M